Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPK850 in Retinitis Pigmentosa Due to RLBP1 Mutations
NCT03374657Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Primary completion
- May 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of CPK850 in retinitis pigmentosa (RP), sponsored by Novartis. Started Aug 2018; status: completed.
02
Drugs
CPK850
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT03374657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03374657.